If you’ve been struggling with insomnia for more than a few weeks and you’ve mentioned it to your GP, there’s a reasonable chance you walked out with a prescription. Benzodiazepines, Z-drugs like zopiclone, or perhaps a newer option like suvorexant. These medications work — in the short term. But they come with dependence risks, rebound insomnia on withdrawal, and they don’t address the underlying problem.

Every major sleep medicine guideline in the world — from the Australasian Sleep Association, the American Academy of Sleep Medicine, the European Sleep Research Society, and the British Sleep Society — recommends cognitive behavioural therapy for insomnia (CBT-I) as the first-line treatment for chronic insomnia. Not as an alternative to medication. As the preferred approach.

So why do most Australians with chronic insomnia never receive it?

What CBT-I Actually Involves

CBT-I is a structured, typically short-term treatment — usually four to eight sessions — that targets the thoughts and behaviours maintaining insomnia. It’s not general relaxation training or sleep hygiene advice (though those can be components). It’s a specific clinical protocol with several core elements.

Sleep restriction therapy is often the most effective — and most uncomfortable — component. Patients limit their time in bed to match their actual sleep duration. If you’re sleeping five hours but spending eight hours in bed, your prescribed time in bed starts at five hours. This creates mild sleep deprivation, which consolidates sleep and strengthens the sleep drive. Time in bed is gradually increased as sleep efficiency improves.

Stimulus control re-associates the bed with sleep rather than wakefulness. The rules are simple: go to bed only when sleepy, get out of bed if you can’t sleep within 15 to 20 minutes, don’t watch TV or scroll your phone in bed, use the bed only for sleep and intimacy.

Cognitive restructuring addresses the anxious thoughts that perpetuate insomnia. “If I don’t sleep tonight I won’t function tomorrow.” “I need eight hours or I’ll get sick.” These beliefs, while understandable, create hyperarousal that makes sleep harder. CBT-I helps patients develop more realistic and less catastrophic thinking about sleep.

Relaxation training and sleep hygiene education round out the programme, though these alone are insufficient for chronic insomnia. They’re supplementary, not standalone interventions.

What the Evidence Shows

The evidence base for CBT-I is exceptionally strong. A 2022 meta-analysis in The Lancet examined 89 randomised controlled trials and found that CBT-I produced significant improvements in sleep onset latency (falling asleep faster), wake after sleep onset (staying asleep longer), sleep efficiency, and subjective sleep quality.

Critically, the effects are durable. Unlike medication, which stops working when you stop taking it, the benefits of CBT-I persist months and even years after treatment ends. A follow-up study published in JAMA Internal Medicine found improvements maintained at 12 months post-treatment in over 70 percent of patients.

CBT-I also outperforms medication in head-to-head trials for long-term outcomes. A landmark study in Annals of Internal Medicine compared CBT-I with zolpidem over six months. Both were effective initially. At follow-up, the CBT-I group maintained their gains. The medication group had relapsed.

For patients with comorbid conditions — depression, chronic pain, anxiety — CBT-I still works. Multiple trials have shown that treating insomnia with CBT-I improves the comorbid condition as well, particularly depression. It’s not just a sleep treatment. It addresses a factor that drives other health problems.

The Access Problem in Australia

Here’s where it gets difficult. CBT-I works. Everyone agrees it works. But accessing it in Australia is genuinely hard.

The number of psychologists and sleep specialists trained in CBT-I delivery is small relative to demand. Most clinical psychologists learn general CBT in training but don’t receive specific CBT-I training. Sleep physicians may recommend it but don’t typically deliver it themselves.

Medicare funds psychological therapy through the Better Access initiative, providing up to 10 sessions per year with a referred psychologist. CBT-I fits within this framework, but finding a psychologist who actually offers structured CBT-I — not just general sleep counselling — takes effort. The Australian Psychological Society’s “Find a Psychologist” service allows filtering by specialisation, which can help.

Private sleep clinics in major cities increasingly offer CBT-I programmes, often delivered by psychologists embedded within the sleep service. Costs vary — typically $150 to $250 per session with partial Medicare rebate if referred through a mental health treatment plan.

For regional Australians, telehealth has been transformative. Several Australian providers now deliver CBT-I via video consultation, which works well for a treatment that’s essentially structured conversation and behavioural coaching.

Digital CBT-I Options

Digital CBT-I programmes — structured online courses that deliver the same treatment components without a live therapist — have emerged as a scalable option. SHUTi and Sleepio are two programmes with strong clinical evidence. Both have been tested in randomised controlled trials and shown efficacy comparable to face-to-face delivery for mild-to-moderate insomnia.

These programmes typically cost less than a single therapy session and can be accessed immediately. They’re not right for everyone — patients with severe insomnia, significant psychiatric comorbidity, or safety concerns (e.g., drowsy driving) should see a clinician. But for many people, digital CBT-I is a reasonable and evidence-based starting point.

The Bottom Line

If you’ve been dealing with insomnia for more than three months, CBT-I should be your first consideration — ahead of medication. Ask your GP for a referral to a psychologist with specific CBT-I experience. If that’s not available locally, look into telehealth options or validated digital programmes. The evidence is clear, the treatment is effective, and the benefits last.